Moe Alsumidaie’s Post

The cell therapy question is shifting from “can you get approved?” to “can you scale?” — and Mesoblast Limited is now the test case. With Ryoncil as the first FDA-approved MSC therapy, its upcoming webcast offers the clearest signal yet on whether allogeneic cell therapies can move from niche academic use to durable commercial adoption in high-acuity transplant settings. Execution now matters more than milestones: center activation, payer confidence in consistency and outcomes, and a real-world evidence engine that earns its premium. If Mesoblast gets this right, it establishes the playbook for inflammatory and cardiovascular expansion — where volume, economics, and long-term value become decisive. A platform flywheel is possible; a single-asset plateau is the risk. What will be the tipping point for payers and clinicians to treat allogeneic cell therapy as standard hospital medicine rather than a specialized exception? 𝐑𝐞𝐚𝐝 𝐌𝐨𝐫𝐞: https://lnkd.in/gY9DRjkt #CellTherapy #Biotech #CommercialStrategy #RegenerativeMedicine #GVHD Tao Wang Christopher James